Understanding heterogeneity of treatment effect in prostate cancer
Authors:
- C. Daniel MullinsCMC. Daniel Mullins
- Arif HussainAHArif Hussain
- 1 May 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 27 (3) , 209-216
Abstract
In the era of personalized medicine, oncologists seek to tailor treatments for their patients based on indicators of differential response to treatment. We first provide a conceptual explanation of heterogeneity of treatment effect using prostate cancer as a case study and review studies that test whether Gleason score has a role in modifying the effectiveness of androgen deprivation therapy in men newly diagnosed with metastatic prostate cancer. Depending on the study design, setting, and population, the median time to develop castration-resistant prostate cancer ranges from 12 to 23 months among men with M1 disease on androgen deprivation therapy, and the median time from diagnosis to mortality in such patients ranges from 23 to 37 months. Patients with higher Gleason scores have a significantly shorter time to developing castration-resistant prostate cancer compared with patients with lower Gleason scores. However, data suggest that Gleason score does not have a role in modifying the survival benefit associated with androgen deprivation therapy. Androgen deprivation therapy has heterogeneous effects in men with metastatic prostate cancer related to the time of developing castration resistance. However, survival benefit from androgen deprivation therapy does not appear to depend on Gleason score.Keywords
This publication has 27 references indexed in Scilit:
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a modelJournal of Comparative Effectiveness Research, 2013
- Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancerCritical Reviews in Oncology/Hematology, 2013
- From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerBMC Medical Research Methodology, 2012
- Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern PlotJournal of Clinical Oncology, 2010
- Uncertainty in Assessing Value of Oncology TreatmentsThe Oncologist, 2010
- Prostate CancerJournal of the National Comprehensive Cancer Network, 2010
- Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice GuidelineJournal of Clinical Oncology, 2007
- Evidence‐Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with AveragesThe Milbank Quarterly, 2004
- Prognostic value of the Gleason score in prostate cancerBJU International, 2002